BCR and intrahepatic cholangiocarcinoma: For the latter, FISH evidence of BCR::ABL1 in granulocytes as well as lymphoblasts is required as there is evidence that these entities may require different management.24 Both classifications include B-ALL with BCR-ABL1-like features as an entity (previously provisional) with promising targeted therapy response in preclinical models.25 The ICC further divides this category into ABL-1 class rearranged, JAK-STAT activated and NOS, as the ABL-1 class responds better to TKI therapy.26